ALESSANDRA FERRAJOLI to Dose-Response Relationship, Drug
This is a "connection" page, showing publications ALESSANDRA FERRAJOLI has written about Dose-Response Relationship, Drug.
Connection Strength
0.405
-
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29; 118(13):3489-98.
Score: 0.054
-
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec; 29(6):1206-12.
Score: 0.050
-
Bendamustine in relapsed or refractory chronic lymphocytic leukemia. Haematologica. 2005 Oct; 90(10):1300A.
Score: 0.036
-
Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
Score: 0.024
-
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
Score: 0.022
-
Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
Score: 0.022
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.021
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.021
-
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904.
Score: 0.018
-
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015 Nov 01; 121(21):3869-76.
Score: 0.018
-
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
Score: 0.017
-
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9.
Score: 0.017
-
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82.
Score: 0.012
-
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
Score: 0.010
-
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302.
Score: 0.010
-
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
Score: 0.010
-
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
Score: 0.010
-
Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
Score: 0.009
-
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22.
Score: 0.009
-
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
Score: 0.009
-
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9.
Score: 0.008